I thought the whole point of cancelling the docuseries and other shows was to get back to “real news”? And now they want a comedian on prime time? Talk about lack of vision.

I didn’t specify anything about whether newer drugs fall into this category, but it was very routine that older targeted inhibitors (especially kinase inhibitors like you said) were approved in the past 15 years (not that long ago!! I was in graduate school at that time) for very marginal benefits. So yeah, there are way better drugs now but drugs with marginal benefit were being approved “back then” because there was nothing better and because survival was really dismal.

I’ll have to do a bit of research, but off the top of my head there are a couple of drugs that are in that range: Vemurafenib (metastatic lung cancer, ~3-4 months OS improvement), Crizotinib (~4 months), trodelvy (3.2 months for metastatic triple negative BC), trastuzumab (gastric cancer, <3 months), cetixumab (CRC, 1.5 months).

Considering that there are plenty of oncology drugs that give one month of OS because of the dismal outcomes of specific cancers, this is a sure thing. Getting this data in a phase III trial just seals it.

This will for sure be approved shortly.

A little? You’re understating it.

There are therapeutic vaccines and prophylactic vaccines.

I think this is at the heart of the issue. The Chinese government knows that the health care system cannot handle COVID surges. Even with the camps and ancillary facilities, it wouldn’t be able to handle a “back to normal” approach.

China has billions of citizens in cities way more dense than the USA. Imagine what would happen if ICUs started to fill up…

There’s no point re-watching 1899 — it’s nowhere near as complicated as Dark.

They’re not. If you read the article it says they’re discussing making an in house division rather than 3rd party commissions.